27 August, 2016. Manchester, UK. Prous Institute for Biomedical Research is to present the 2016 Prous Institute – Overton & Meyer Award to Professor Jan Steyaert, at the XXIV International Symposium on Medicinal Chemistry organized by the European Federation of Medicinal Chemistry (EFMC).
The award, conferred every two years, recognizes outstanding contributions to the development of new technologies in the field of medicinal chemistry and acknowledges the awardee’s contribution to the discovery and development of innovative technologies that advance the field.
Prof Steyaert has pioneered the use of nanobodies for chaperone-assisted X-ray crystallography aiming at the highest hanging fruits of structural biology including membrane proteins, amyloidogenic proteins, and multiprotein complexes. Recent work focuses on exploiting the conformational complexity of therapeutic targets for nanobody-enabled drug discovery.
Prof Steyaert is currently Director of the Structural Biology Research Centre at Vrije Universiteit Brussels (VUB) and Deputy-Director and group leader of the Structural Biology Research Center of the Vlaams Instituut voor Biotechnologie (VIB).
The award will be presented during the XXIV International Symposium on Medicinal Chemistry (EFMC-ISMC 2016), to be held on August 28 – September 1, 2016 in Manchester, United Kingdom.
About Prous Institute for Biomedical Research
Prous Institute for Biomedical Research is a research company comprised of two business units: drug discovery and in silico technologies. Prous Institute’s drug discovery and research unit is committed to discovering novel therapies through the application of its proprietary drug discovery platform, Symmetry. Prous Institute’s in silico technologies unit focuses on the research, development and commercialization of chemoinformatics and toxicity prediction tools for drug discovery and safety screening.
Prous Institute for Biomedical Research was founded as a spin-off from the leading scientific information provider, Prous Science (acquired by Thomson Reuters in 2007), in order to put into practice innovative in silico approaches to accelerate drug discovery.